V934
Total Payments
$272,050
Transactions
23
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $272,050 | 23 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $269,550 | 22 | 99.1% |
| Consulting Fee | $2,500 | 1 | 0.9% |
Payments by Type
Research
$269,550
22 transactions
General
$2,500
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934,V935 hTERT Vaccination in Cancer Patients with Selected Solid Tumors | Merck Sharp & Dohme Corporation | $269,550 | 0 |
Top Doctors Receiving Payments for V934
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Palo Alto, CA | $269,550 | 22 |
| , M.D | Gastroenterology | Stanford, CA | $2,500 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $272,050
Product Information
- Type Drug
- Total Payments $272,050
- Total Doctors 1
- Transactions 23
About V934
V934 is a drug associated with $272,050 in payments to 1 healthcare providers, recorded across 23 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2019. In 2019, $272,050 was paid across 23 transactions to 1 doctors.
The most common payment nature for V934 is "Unspecified" ($269,550, 99.1% of total).
V934 is associated with 1 research study, including "A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934,V935 hTERT Vaccination in Cancer Patients with Selected Solid Tumors" ($269,550).